After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?

Schmitt, Jochen

doi:10.1111/bjd.16505

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, multiple clinical trials have demonstrated the efficacy of targeted therapy involving the blocking of cytokines or mediators that play a pivotal role in the pathogenesis of AD. Dupilumab is currently the only biologic drug that has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of adult patients with inadequately controlled moderate-to-severe AD [ 12 ]. Biological drugs appear to be promising treatments for adult AD patients because they offer more convenient dose regimens and allow less frequent laboratory monitoring than other systemic therapies, as well as having fewer side effects [ 1 ].…”

Section: Biologic Drugsmentioning

confidence: 99%

Treatment of Atopic Dermatitis with Biologic Drugs

Fabbrocini

Napolitano

Megna

et al. 2018

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease which predominately affects children and usually clears up during infancy or childhood. However, AD may persist with a chronic relapsing course until adulthood or develop at a later age. AD treatment can often be complicated. Treating moderate-to-severe AD can be challenging: only a few therapeutic options are available, with cyclosporine being the only approved and labeled systemic drug. In the last few years, advances in the knowledge of AD pathogenesis have been made that can provide the basis for developing new topical and systemic drugs. Among them, biologic drugs targeting specific cytokines involved in the development of the disease will probably revolutionize AD therapy. Currently, dupilumab, a monoclonal antibody that binds to the shared alpha chain subunit of the receptors for IL-4 and IL-13, is the only biologic drug licensed for the treatment of AD in adults. However, other biologic drugs that selectively target some key cytokines in AD pathogenesis (IL-13, IL-31, and IL-22) are also being studied. In this review, we discuss all of the biologic drugs that have been studied for AD treatment.

show abstract

Section: Biologic Drugsmentioning

confidence: 99%